Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: NRG-CC004.
Debra L BartonStephanie L PughPatricia A GanzSteven C PlaxeBridget F KoontzJeanne CarterNatalya Greyz-YusupovSeth J PageKendrith M RowlandErnie P BalcuevaSobia NabeelJack B BasilMatthew L HillCarolyn Y MullerMaria C BellSnehal DeshmukhLisa A KachnicPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Bupropion was not more effective than placebo in improving the desire subscale of the FSFI. Subscale and total scores of the FSFI demonstrated dysfunction throughout the 9 weeks of the study. More research is needed to support sexual function in female cancer survivors.